NeuBase Therapeutics, Inc. (NBSE): Price and Financial Metrics
GET POWR RATINGS... FREE!
NBSE Stock Price Chart Interactive Chart >
NBSE Price/Volume Stats
| Current price | $1.02 | 52-week high | $5.51 |
| Prev. close | $0.96 | 52-week low | $0.89 |
| Day low | $0.98 | Volume | 129,000 |
| Day high | $1.04 | Avg. volume | 114,687 |
| 50-day MA | $1.42 | Dividend yield | N/A |
| 200-day MA | $2.51 | Market Cap | 32.90M |
NeuBase Therapeutics, Inc. (NBSE) Company Bio
NeuBase Therapeutics, Inc. produces and distributes pharmaceutical products. The Company offers drugs for the treatment of dominant genetic disorders and oncogenic mutations causing cancers. NeuBase Therapeutics serves patients in the United States.
Latest NBSE News From Around the Web
Below are the latest news stories about NeuBase Therapeutics Inc that investors may wish to consider to help them evaluate NBSE as an investment opportunity.
NeuBase Therapeutics Reports Business Update and Financial Results for the First Quarter of Fiscal Year 2022Investigational New Drug (IND)-enabling studies for the myotonic dystrophy type 1 (DM1) program development candidate continue as planned; invited to present new rodent pharmacokinetic (PK) and bioavailability data in an oral presentation at an upcoming scientific meeting; expects to submit an IND application to the U.S. Food and Drug Administration (FDA) in the fourth quarter (Q4) of calendar year (CY) 2022Good Manufacturing Practice (GMP) manufacturing to support Phase 1/2 clinical trials for |
Is NeuBase Therapeutics (NASDAQ:NBSE) In A Good Position To Invest In Growth?Just because a business does not make any money, does not mean that the stock will go down. For example, although... |
NeuBase Therapeutics hires new chief financial officerNeuBase Therapeutics, a Pittsburgh-based developer of genetic medicines, announced that it has hired Todd Branning as its new chief financial officer. |
NeuBase Therapeutics names Phathom''s Todd Branning as new CFONeuBase Therapeutics (NBSE) appoints Todd P. Branning as the company''s new chief financial officer. Prior to joining NeuBase, Branning served as CFO of Phathom Pharmaceuticals (PHAT)… |
NeuBase Therapeutics Appoints Todd P. Branning Chief Financial OfficerPITTSBURGH and CAMBRIDGE, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, announced today the appointment of Todd P. Branning as Chief Financial Officer (CFO). Mr. Branning has more than 25 years of experience leading corporate finance and accounting, tax, financial planning and analysis, and |
NBSE Price Returns
| 1-mo | -14.29% |
| 3-mo | -28.17% |
| 6-mo | -67.20% |
| 1-year | -80.27% |
| 3-year | -66.34% |
| 5-year | -91.77% |
| YTD | -63.70% |
| 2021 | -59.80% |
| 2020 | -2.92% |
| 2019 | 300.00% |
| 2018 | -95.16% |
| 2017 | 24.00% |
Loading social stream, please wait...